IMIDomics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1000 4th St Ste 500, San Francisco, Cali...Website
www.imidomics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About IMIDomics
IMIDomics, Inc. is a privately held global biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs). Headquartered in San Rafael, California, IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall dHebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology.Explore more
IMIDomics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IMIDomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if IMIDomics is spiking on competitors!
Check if IMIDomics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when IMIDomics launches new products
Congratulate Masked Content for being promoted to Masked Content at IMIDomics
Earning: See what the market has to say on IMIDomics recently announced quarterly report
IMIDomics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once IMIDomics has new funding data
Click to see if IMIDomics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at IMIDomics
Find more new buyers
Compare Similar Companies to IMIDomics
Compare insights from companies similar to IMIDomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IMIDomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
IMIDomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about IMIDomics.
IMIDomics financials insights
Gather financial insights about IMIDomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$16.5M
IMIDomics Tech Stack
A closer look at the technologies used by IMIDomics
Most Recent Scoops
New Hire
Executive Move
Funding
Funding
, an immune-mediated inflammatory disease treatment provider, has recently secured debt funding from DNS Capital. Financial details have not been disclosed.
Funding
IMIDomics News & Media
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), announced today that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company. This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients. In 2016, IMIDomIMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team
SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), proudly announces the addition of Dr. Eric Perakslis, a highly accomplished pharmaceutical R&D and digital sciences executive, as Senior Vice President and Chief Technology Officer (CTO). In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science. These additions will playIMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs
SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategic license and collaboration agreement with the University of Barcelona (UB). Under this agreement, IMIDomics has licensed cutting-edge technology and expertise from UB to advance research aimed at understanding and treating IMIDs. Dr. H. Daniel Perez, Chief Development Officer at IMIDomics, expressed hisIMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target with the potential to treat I
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding IMIDomics
Sign Up For FreeTo access detailed company insights
IMIDomics, Inc. is a privately held global biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs). Headquartered in San Rafael, California, IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall... Read More
